ReviewInfluenza vaccine responses in older adults
Research highlights
▶ Immune senescence leads to increased susceptibility to influenza and loss of vaccine efficacy. ▶ Age-related changes in innate and adaptive immune function challenge new vaccine development. ▶ Antibody titers as a sole measure of influenza vaccine efficacy may fail to detect enhanced clinical protection. ▶ Novel immunologic targets and correlates of protection are needed to develop effective vaccines.
Section snippets
Influenza—a significant cause of morbidity in older adults
Aging is associated with a decline in humoral, innate, and adaptive cell-mediated immunity and a dramatic increase in late-life morbidity and mortality from influenza. The full impact of influenza is increasingly recognized as an illness that goes well beyond pneumonia and influenza statistics. Peak months of mortality due to respiratory illness, ischemic heart disease, cerebrovascular events and diabetes in adults 70 years and older coincide with annual influenza epidemics, suggesting that
Link to immune senescence
A decline in immune function is a hallmark of aging and affects the ability to resist influenza infection and respond to vaccination. It is recognized that multiple components of immune function, particularly cell-mediated immunity, are affected during the aging process. As a consequence, there has been a paradigm shift in understanding the limitations of antibody titers as a sole measure of influenza vaccine efficacy in older people (Bernstein et al., 1999, Gardner et al., 2001, Murasko et
Cross-reactivity of the T-cell response
In contrast to the strain-specific antibody response of B-cells, viral epitopes that stimulate T helper cells (Th) and cytotoxic T lymphocytes (CTL) responses are more conserved across different strains of influenza and appear not to degrade with antigenic drift (Effros et al., 1977, Butchko et al., 1978, Russell and Liew, 1979). Virus is taken up and processed by antigen-presenting cells (APC) such as macrophages and dendritic cells, and the resulting peptides are presented with the major
High-dose vs. adjuvanted influenza vaccines
Two main strategies are being used to improve the response to influenza vaccination in older adults and include changing the content of the vaccine and evaluating alternate routes of administration to the current practice of intramuscular injection. Increasing the amount of influenza viral antigen (standardized according to HA content), adding an adjuvant to seasonal influenza vaccine, or using live-attenuated influenza strains are some of the strategies being pursued. In the case of influenza
Summary
Rising hospitalization and death rates due to influenza over the last two decades in spite of widespread influenza vaccination programs, call for more effective influenza vaccines in the older population. A greater understanding of how age-related changes and their interaction with common chronic diseases in older persons is to needed to develop new influenza vaccines with enhanced protection in this population. There have been major advances in vaccine technology but the phases of clinical
References (126)
- et al.
Reduction in mortality associated with influenza vaccine during 1989–90 epidemic
Lancet
(1995) - et al.
Reversal of age-associated thymic atrophy: treatments, delivery, and side effects
Exp. Gerontol.
(2008) - et al.
Immune response to influenza vaccination in a large healthy elderly population
Vaccine
(1999) - et al.
Influenza A virus specific T cell immunity in humans during aging
Virology
(2002) - et al.
In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses
Vaccine
(2009) - et al.
T cell subset-specific susceptibility to aging
Clin. Immunol.
(2008) - et al.
Annually repeated influenza vaccination improves humoral responses to several influenza virus strains in healthy elderly
Vaccine
(1997) - et al.
The virosomal influenza vaccine Invivac((R)): immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad((R))) in elderly subjects
Vaccine
(2006) - et al.
Antibody induction by virosomal. MF59-adjuvanted, or conventional influenza vaccines in the elderly
Vaccine
(2007) - et al.
Reduction of T cell-derived ghrelin enhances proinflammatory cytokine expression: implications for age-associated increases in inflammation
Blood
(2009)